NXGL NEXGEL INC

NEXGEL Launches Turfguard to Treat Painful Turf Burns and Protect Sports-Related Wounds

NEXGEL Launches Turfguard to Treat Painful Turf Burns and Protect Sports-Related Wounds

LANGHORNE, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that it has launched a new product dubbed Turfguard, a unique hydrogel dressing for soothing turf burn and protecting athletic wounds. Turfguard’s sterile silver patches, cleared by the U.S. Food and Drug Administration, kill 99 percent of staph, MRSA and strep.

Turfguard patches maintain a moist wound environment and aid in removing non-viable tissues from the wound. The patches do not pull on delicate, new or healing skin and provide an instant cooling relief to the affected area. Manufactured out of the Company’s facility in Langhorne, Pa., Turfguard is available for purchase on .

“For athletes, turf burns and skin abrasions are often a common, unfortunate part of the game,” said Adam Levy, Chief Executive Officer, NEXGEL. “Additionally, turf fields and other shared equipment frequently house harmful bacteria, such as MRSA, that can lead to serious health complications. NEXGEL’s proprietary Turfguard patches can be used on superficial burns, abrasions or lacerations and has been shown to kill staph, MRSA and strep. What’s more, these dressings have a high-water content making them delicate on the skin and helping the area to heal quickly. This product is a must-have for training rooms across football, lacrosse, wrestling, gymnastics and many other applicable sports.”

About NEXGEL, INC.

NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Investor Contact:

Valter Pinto

KCSA Strategic Communications

212.896.1254

Media Contacts:

Raquel Cona / Michaela Fawcett

KCSA Strategic Communications

212.896.1204 / 978.995.4683

/

###



EN
08/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEXGEL INC

 PRESS RELEASE

NEXGEL Announces Consideration Terms of Agreement to License and Acqui...

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDA...

 PRESS RELEASE

NEXGEL Signs Definitive Agreement to License and Acquire Transformativ...

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding ...

 PRESS RELEASE

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisitio...

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acqu...

 PRESS RELEASE

NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis ...

NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company’s previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric ...

 PRESS RELEASE

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its drug delivery technology LANGHORNE, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applica...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch